FSTL3, follistatin like 3, 10272

N. diseases: 33; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0400966
Disease: Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
0.010 AlteredExpression disease BEFREE In more advanced stages, FSTL3 levels are higher in NASH compared to SS and, within NAFLD patients, in those with more severe lobular and portal inflammation. 31690932 2020
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion
0.010 Biomarker phenotype BEFREE It was previously reported that follistatin-like 3(FSTL3), an activin A binding protein, contributes to the invasion and migration of trophoblast. 31810141 2020
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.010 Biomarker disease BEFREE All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression. 31815869 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.010 Biomarker disease BEFREE All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression. 31815869 2019
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.010 Biomarker group BEFREE We assessed the predictive value of GAL3 (galectin-3), FSTL3 (follistatin-like 3 peptide), and NT-proBNP (N-terminal pro-B-type natriuretic peptide) to identify stage B MHD in young obese participants free of clinically evident cardiovascular disease. 30929550 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.010 AlteredExpression disease BEFREE We investigated this hypothesis in humans by studying the physiology of a possible glycaemia-follistatin feedback loop, that is, whether glucose, but not lipid intake (oral or intravenous), can regulate circulating FST and FSTL3 in healthy humans (n = 32), whether the levels of follistatins change in response to various types of bariatric operation in morbidly obese individuals, with or without type 2 diabetes (n = 41), and whether such changes are associated prospectively with improvement of glucose homeostasis/insulin sensitivity. 30393997 2019
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.010 GeneticVariation group BEFREE Framingham 10-year stroke risk (FSRP-10) quantified CVD-RFs. 30980900 2019
CUI: C0039263
Disease: Takayasu Arteritis
Takayasu Arteritis
0.010 Biomarker disease BEFREE Considering this, we further built a logistic regression model based on multiple cytokines, including CA (cancer antigen) 125, FLRG (follistatin-related protein), IGFBP (insulin-like growth factor-binding protein)-2, CA15-3, GROa (growth-regulated alpha protein), LYVE (lymphatic vessel endothelial hyaluronic acid receptor)-1, ULBP (UL16-binding protein)-2, and CD (cluster of differentiation) 99, with an area under the curve reaching 0.909 for discriminating TA activity status. 30645172 2019
CUI: C0242339
Disease: Dyslipidemias
Dyslipidemias
0.010 Biomarker group BEFREE FSTL3 as adipokine takes part in dyslipidemia and inflammatory response, but the association of FSTL3 with atherosclerosis is unclear. 31815869 2019
CUI: C0004096
Disease: Asthma
Asthma
0.010 Biomarker disease BEFREE To quantify the abundance of the total proteome FSTL3 and activin A in supernatants of differentiated BEC cultures from healthy children and children with asthma, we performed mass spectrometry and ELISA. 29394092 2018
CUI: C0524620
Disease: Metabolic Syndrome X
Metabolic Syndrome X
0.010 AlteredExpression disease BEFREE Activin A, activin B, follistatin, and FSTL3 were measured in (1) 80 subjects divided according to age (young vs old) and fitness status (active vs sedentary) before and after exercise at 70% maximal oxygen consumption (VO2max), followed by 90% of VO2max until exhaustion; and (2) 23 subjects [9 healthy and 14 with metabolic syndrome (MetS)] who completed four sessions: no exercise, high-intensity interval exercise, continuous moderate-intensity exercise, and resistance exercise for up to 45 minutes. 30085147 2018
CUI: C2945695
Disease: Limb ischemia
Limb ischemia
0.010 Biomarker disease BEFREE When iPS-ECs overexpressing FSTL3 were subcutaneously injected in in vivo angiogenic model or intramuscularly injected in a hind limb ischemia NOD.CB17-Prkdcscid/NcrCrl SCID mice model, FSTL3 significantly induced angiogenesis and blood flow recovery, respectively. 29569797 2018
CUI: C0085207
Disease: Gestational Diabetes
Gestational Diabetes
0.010 AlteredExpression phenotype BEFREE There were no significant differences in serum FSTL3 levels (p = 0.578) between the GDM group and the GDM-free control group. 27623975 2017
CUI: C0853879
Disease: Invasive carcinoma of breast
Invasive carcinoma of breast
0.010 AlteredExpression disease BEFREE FSTL3 expression in invasive breast cancer is inversely associated with tumor size and nuclear grade but it does not predict disease relapse in the short term. 28178680 2017
CUI: C1561643
Disease: Chronic Kidney Diseases
Chronic Kidney Diseases
0.010 AlteredExpression group BEFREE Moreover, mFSTL3 mRNA expression was investigated in an animal CKD model, that is, eNOS-/-db/db mice, and compared with littermate controls. 28339962 2017
CUI: C1565489
Disease: Renal Insufficiency
Renal Insufficiency
0.010 Biomarker disease BEFREE In both human CKD and AKD, renal dysfunction remained the strongest independent predictor of FSTL3 serum concentrations in multivariate analyses. 28339962 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.010 Biomarker disease BEFREE Both FSTL3-knockout and FST288-only mice had extensive hepatic steatosis and elevated hepatic triglyceride content. 23533219 2013
CUI: C1397307
Disease: Cardiac fibrosis
Cardiac fibrosis
0.010 Biomarker disease BEFREE We found that FSTL3 is necessary for this response and for the induction of cardiac fibrosis. 22915069 2012
CUI: C3839507
Disease: Diminished ovarian reserve
Diminished ovarian reserve
0.010 Biomarker disease BEFREE Forty-eight transcripts were differentially expressed, including CXXC finger protein 5 (CXXC5), forkhead box C1 (FOXC1) (down-regulated in DOR) as well as connective tissue growth factor (CTGF), follistatin-like 3 (FSTL3), prostaglandin-endoperoxide synthase 2 (PTGS2) and suppressor of cytokine signaling 2 (SOCS2) (up-regulated in DOR). 22246450 2012
CUI: C0013537
Disease: Eclampsia
Eclampsia
0.010 AlteredExpression disease BEFREE Overproduction of the follistatin-related gene protein in the placenta and maternal serum of women with pre-eclampsia. 17617189 2007
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms
0.010 AlteredExpression group LHGDN Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth. 17671190 2007
CUI: C0023903
Disease: Liver neoplasms
Liver neoplasms
0.010 AlteredExpression group LHGDN Expression levels of follistatin, follistatin-like 3, and activin subunits beta(A) as well as beta(E) were investigated in chemically induced rat and human liver tumours by real-time PCR and immunohistochemistry. 16935389 2006
CUI: C0003873
Disease: Rheumatoid Arthritis
Rheumatoid Arthritis
0.010 AlteredExpression disease BEFREE Follistatin-related protein gene (FRP) is expressed in the synovial tissues of rheumatoid arthritis, but its polymorphisms are not associated with genetic susceptibility. 15638044 2005
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.010 AlteredExpression group BEFREE The expression of NEDD8, calponin, and the follistatin-related protein in normal prostate tissues is a novel finding and the role of these important functional proteins in normal prostate and their loss or reduced expression in prostate malignancy warrants further investigations. 11757036 2002
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.010 AlteredExpression group BEFREE The expression of NEDD8, calponin, and the follistatin-related protein in normal prostate tissues is a novel finding and the role of these important functional proteins in normal prostate and their loss or reduced expression in prostate malignancy warrants further investigations. 11757036 2002